← Back to Search

Virus Therapy

Exercise for COVID-19 Immunity (VIC Trial)

N/A
Waitlist Available
Led By Forrest L Baker, PhD
Research Sponsored by Forrest Baker
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Chronic/debilitating arthritis
Bedridden in the past three months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the effects of exercise on anti-viral immunity against many types of common viruses before and after vaccination.

Who is the study for?
Healthy volunteers aged 18-44 who are 'low risk' for exercise, have been vaccinated or recovered from COVID-19, and meet AHA/ACSM criteria can join. They'll need to commit to several visits totaling about 11.5 hours.
What is being tested?
The study is testing if exercise boosts immunity against viruses like COVID-19 before and after vaccination. Participants will do an exercise test and give blood samples at different exertion levels.
What are the potential side effects?
There may be minimal side effects related to the exercise protocol or blood collection, such as muscle soreness or bruising where the blood is drawn.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have long-lasting, severe arthritis.
Select...
I have not been bedridden in the past three months.
Select...
My BMI is over 30, or my waist is larger than 102cm (men) / 88cm (women).
Select...
I do not have multiple CVD risk factors like family history, high blood pressure, high cholesterol, pre-diabetes, or high inflammation markers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine IFN-γ concentration after whole blood stimulation with SARS-CoV-2 peptides
Determine IFN-γ spot forming cells after stimulation with SARS-CoV-2 peptides
Determine SARS-CoV-2 T-cell phenotype
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VaccineExperimental Treatment1 Intervention
Participants who elect to receive the vaccine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVID-19 Vaccine
2023
Completed Phase 3
~16730

Find a Location

Who is running the clinical trial?

Forrest BakerLead Sponsor
University of ArizonaLead Sponsor
535 Previous Clinical Trials
159,874 Total Patients Enrolled
Forrest L Baker, PhDPrincipal InvestigatorThe University of Arizona
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top